|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
LT4342992T
(lt)
|
2009-05-02 |
2025-08-25 |
Genzyme Corporation |
Genų terapija, skirta neurodegeneracinių sutrikimų gydymui
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
CA2833908C
(en)
|
2010-04-23 |
2021-02-09 |
University Of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
JP2013533847A
(ja)
|
2010-04-23 |
2013-08-29 |
ユニバーシティ オブ マサチューセッツ |
コレステロール関連障害のａａｖベースの治療
|
|
CA2833905C
(en)
|
2010-04-23 |
2019-09-10 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
EP3318634A1
(en)
|
2011-04-21 |
2018-05-09 |
University of Massachusetts |
Raav-based compositions and methods for treating diseases involving dominant-negative or gain of function mutations
|
|
JP6072772B2
(ja)
|
2011-04-22 |
2017-02-01 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
変異体キャプシドを有するアデノ関連ウイルスビリオンおよびその使用方法
|
|
EP3622821A1
(en)
|
2013-05-15 |
2020-03-18 |
Regents of the University of Minnesota |
Adeno-associated virus mediated gene transfer to the central nervous system
|
|
WO2014194132A1
(en)
|
2013-05-31 |
2014-12-04 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
|
WO2015038958A1
(en)
|
2013-09-13 |
2015-03-19 |
California Institute Of Technology |
Selective recovery
|
|
WO2015127128A2
(en)
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
|
AU2015231439B2
(en)
|
2014-03-17 |
2019-11-14 |
Adverum Biotechnologies, Inc. |
Compositions and methods for enhanced gene expression in cone cells
|
|
EP3750907A3
(en)
|
2014-03-18 |
2021-04-28 |
University of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
|
IL248102B
(en)
|
2014-05-02 |
2022-07-01 |
Genzyme Corp |
aav vectors for gene therapy of the central nervous system and retina
|
|
SG11201609314XA
(en)
*
|
2014-05-14 |
2016-12-29 |
Esteve Labor Dr |
Adenoassociated virus vectors for the treatment of lysosomal storage disorders
|
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
US10711270B2
(en)
|
2014-10-03 |
2020-07-14 |
University Of Massachusetts |
High efficiency library-identified AAV vectors
|
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
|
EP3209311B1
(en)
|
2014-10-21 |
2024-03-06 |
University of Massachusetts |
Recombinant aav variants and uses thereof
|
|
EA201791805A1
(ru)
|
2015-02-10 |
2018-05-31 |
Джензим Корпорейшн |
ВАРИАНТ СРЕДСТВА ДЛЯ RNAi
|
|
KR102863734B1
(ko)
*
|
2015-02-10 |
2025-09-25 |
젠자임 코포레이션 |
선조체 및 피질로의 바이러스 입자의 향상된 전달
|
|
WO2016131009A1
(en)
|
2015-02-13 |
2016-08-18 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
MY187898A
(en)
|
2015-03-02 |
2021-10-27 |
Adverum Biotechnologies Inc |
Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
|
|
EP3268481B1
(en)
*
|
2015-03-11 |
2020-05-27 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Rpgr vectors for treating x-linked retinitis pigmentosa
|
|
EP3277819B1
(en)
|
2015-03-24 |
2021-03-03 |
The Regents of The University of California |
Adeno-associated virus variants and methods of use thereof
|
|
PT3280432T
(pt)
|
2015-04-06 |
2021-04-22 |
Subdomain Llc |
Polipéptidos que contêm domínio de ligação de novo e seus usos
|
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
|
US20180104289A1
(en)
|
2015-04-08 |
2018-04-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human |
Viral gene therapy as treatment for cholesterol storage disease or disorder
|
|
EP3285780A4
(en)
|
2015-04-24 |
2018-12-19 |
University of Massachusetts |
Modified aav constructions and uses thereof
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
GB201508025D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Fabry disease gene therapy
|
|
CN114606267A
(zh)
|
2015-09-28 |
2022-06-10 |
北卡罗来纳-查佩尔山大学 |
逃避抗体的病毒载体的方法和组合物
|
|
US11426469B2
(en)
|
2015-10-22 |
2022-08-30 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
DK3364997T5
(da)
|
2015-10-22 |
2024-09-30 |
Univ Massachusetts |
Aspartoacylase genterapi til behandling af canavans sygdom
|
|
EP3368054A4
(en)
|
2015-10-28 |
2019-07-03 |
Voyager Therapeutics, Inc. |
REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
|
|
ES2869284T3
(es)
|
2015-12-11 |
2021-10-25 |
California Inst Of Techn |
Péptidos de diana para dirigir virus adenoasociados (AAV)
|
|
SG10201912935WA
(en)
*
|
2015-12-15 |
2020-02-27 |
Genzyme Corp |
Adeno-associated viral vectors for treating mucolipidosis type ii
|
|
US11826433B2
(en)
|
2016-02-02 |
2023-11-28 |
University Of Massachusetts |
Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
|
|
WO2017139643A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
WO2017147477A1
(en)
*
|
2016-02-26 |
2017-08-31 |
University Of Florida Research Foundation, Inc. |
Aav heparin mutants that display significantly improved eye and brain transduction
|
|
EP3440210A4
(en)
|
2016-04-05 |
2019-11-27 |
University of Massachusetts |
COMPOSITIONS AND METHOD FOR SELECTIVELY INHIBITING THE EXPRESSION OF GRAINYHEAD LIKE PROTEIN
|
|
CN107287238B
(zh)
*
|
2016-04-11 |
2020-10-16 |
厦门继景生物技术有限责任公司 |
一种基因载体及其用于治疗雷柏氏先天性黑矇2型疾病的基因治疗药物
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
GB201608046D0
(en)
|
2016-05-09 |
2016-06-22 |
Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The |
Treatment of complement-mediated disorders
|
|
SG11201809643UA
(en)
*
|
2016-05-18 |
2018-12-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
|
WO2017218852A1
(en)
|
2016-06-15 |
2017-12-21 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
BR112019000171A2
(pt)
*
|
2016-07-08 |
2019-10-01 |
Univ Pennsylvania |
métodos e composições para tratamento de distúrbios e doenças envolvendo rdh12
|
|
US11458211B2
(en)
|
2016-07-12 |
2022-10-04 |
The University Of Manchester |
Gene therapy
|
|
MX2019001276A
(es)
|
2016-07-29 |
2019-06-13 |
Univ California |
Viriones de virus adenoasociados con cápside variante y métodos para su uso.
|
|
JP7226801B2
(ja)
*
|
2016-08-16 |
2023-02-21 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
標的遺伝子導入のための方法および組成物
|
|
IL315358A
(en)
*
|
2016-08-18 |
2024-11-01 |
Univ California |
CRISPR-CAS genome engineering using a modular AAV delivery system
|
|
WO2018035457A1
(en)
*
|
2016-08-19 |
2018-02-22 |
Calimmune, Inc. |
Methods and compositions for treating canine conditions using recombinant self-complementary adeno-associated virus
|
|
US11207382B2
(en)
|
2016-08-19 |
2021-12-28 |
University Of Florida Research Foundation, Incorporated |
Compositions for treating conditions using recombinant self-complementary adeno-associated virus
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
MX392374B
(es)
|
2016-09-28 |
2025-03-24 |
Cohbar Inc |
Peptidos terapeuticos relacionados con mots-c.
|
|
EP3518985A4
(en)
*
|
2016-09-29 |
2020-08-05 |
University of Florida Research Foundation, Incorporated |
AAVRH.10 VARIANTS WITH HOST ANTIBODY EXHAUST CAPACITIES AND MODIFIED TISSUE TARGETING PROPERTIES
|
|
EP3526333A4
(en)
|
2016-10-13 |
2020-07-29 |
University of Massachusetts |
AAV CAPSIDE DESIGNS
|
|
CA3040179A1
(en)
|
2016-10-19 |
2018-04-26 |
Adverum Biotechnologies, Inc. |
Modified aav capsids and uses thereof
|
|
AU2017371043B2
(en)
|
2016-12-07 |
2022-12-15 |
University Of Florida Research Foundation, Incorporated |
IL-1Ra cDNAs
|
|
WO2018145009A1
(en)
*
|
2017-02-06 |
2018-08-09 |
University Of Tennessee Research Foundation |
Dna-zyme based methods & compositions for treating huntington's disease
|
|
US11117930B2
(en)
|
2017-02-23 |
2021-09-14 |
Adrx, Inc. |
Peptide inhibitors of transcription factor aggregation
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
CA3059891A1
(en)
|
2017-04-14 |
2018-10-18 |
National Taiwan University |
Gene therapy for aadc deficiency
|
|
WO2018200419A1
(en)
*
|
2017-04-23 |
2018-11-01 |
The Trustees Of The University Of Pennsylvania |
Viral vectors comprising engineered aav capsids and compositions containing the same
|
|
US11752181B2
(en)
*
|
2017-05-05 |
2023-09-12 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating Huntington's disease
|
|
CA3059213A1
(en)
|
2017-05-09 |
2018-11-15 |
University Of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (als)
|
|
CA3061968A1
(en)
|
2017-05-10 |
2018-11-15 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modifying assembly-activating protein (aap)-dependence of viruses
|
|
JP2020523035A
(ja)
|
2017-06-07 |
2020-08-06 |
エーディーアールエックス， インコーポレイテッド |
タウ凝集阻害剤
|
|
US20200121746A1
(en)
*
|
2017-06-30 |
2020-04-23 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsids and methods of use thereof
|
|
CN111448308A
(zh)
|
2017-08-03 |
2020-07-24 |
沃雅戈治疗公司 |
递送aav的组合物和方法
|
|
CA3059995A1
(en)
|
2017-08-28 |
2019-03-07 |
The Regents Of The University Of California |
Adeno-associated virus capsid variants and methods of use thereof
|
|
WO2019060649A1
(en)
*
|
2017-09-22 |
2019-03-28 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE
|
|
AU2018335410B2
(en)
|
2017-09-22 |
2025-04-03 |
Genzyme Corporation |
Variant RNAi
|
|
CN118006607A
(zh)
|
2017-09-22 |
2024-05-10 |
马萨诸塞大学 |
Sod1双表达载体及其用途
|
|
KR102776626B1
(ko)
*
|
2017-10-16 |
2025-03-04 |
비게네론 게엠베하 |
Aav 벡터
|
|
KR102763312B1
(ko)
*
|
2017-10-20 |
2025-02-07 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
치료적으로 유효한 양의 재조합 aav9- 유도 벡터의 망막하 전달을 포함하는 대상체의 원추 광수용체 내 관심의 폴리뉴클레오티드를 발현하는 방법
|
|
CA3082410A1
(en)
|
2017-11-14 |
2019-05-23 |
Arcellx, Inc. |
Multifunctional immune cell therapies
|
|
US11464803B2
(en)
|
2017-11-14 |
2022-10-11 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
|
CA3082080A1
(en)
*
|
2017-11-15 |
2019-05-23 |
Friedrich Miescher Institute For Biomedical Research |
Primate retinal pigment epithelium cell-specific promoter
|
|
DK3710590T3
(da)
*
|
2017-11-15 |
2024-08-12 |
Univ Michigan Regents |
Virale vektorer omfattende rdh12-kodende områder og fremgangsmåder til behandling af nethindedystrofier
|
|
US20190153440A1
(en)
|
2017-11-21 |
2019-05-23 |
Casebia Therapeutics Llp |
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
|
|
CN108085316B
(zh)
*
|
2017-12-25 |
2021-02-09 |
中国人民解放军第四军医大学 |
一种通过抑制微小核糖核酸来促进小鼠视网膜前体细胞体外扩增的方法
|
|
EP3768327A4
(en)
*
|
2018-03-23 |
2022-04-13 |
The Trustees of Columbia University in the City of New York |
GENE EDITING FOR AUTOSOMAL DOMINANT DISEASES
|
|
BR112020020266A2
(pt)
|
2018-04-03 |
2021-01-19 |
Stridebio, Inc. |
Vetores de vírus com evasão de anticorpos
|
|
EP3774852A1
(en)
|
2018-04-03 |
2021-02-17 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
EA202092362A1
(ru)
|
2018-04-03 |
2021-01-11 |
Страйдбайо, Инк. |
Вирусные векторы для нацеливания на ткани глаза
|
|
US12378576B2
(en)
|
2018-04-27 |
2025-08-05 |
Spacecraft Seven, Llc |
Gene therapy for CNS degeneration
|
|
US20210230632A1
(en)
|
2018-05-15 |
2021-07-29 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
CA3099306A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of parkinson's disease
|
|
CA3100066A1
(en)
*
|
2018-05-15 |
2019-11-21 |
President And Fellows Of Harvard College |
Viral vectors exhibiting improved gene delivery properties
|
|
EP3793615A2
(en)
|
2018-05-16 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Directed evolution of aav to improve tropism for cns
|
|
WO2019232517A1
(en)
*
|
2018-06-01 |
2019-12-05 |
University Of Florida Research Foundation, Incorporated |
Compositions and methods for treatment of dominant retinitis pigmentosa
|
|
US12163129B2
(en)
|
2018-06-08 |
2024-12-10 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
PH12021550254A1
(en)
|
2018-08-03 |
2023-02-06 |
Genzyme Corp |
Variant rnai against alpha-synuclein
|
|
CN109022487A
(zh)
*
|
2018-08-15 |
2018-12-18 |
上海市第人民医院 |
一种表达p65的基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物
|
|
WO2020068990A1
(en)
|
2018-09-26 |
2020-04-02 |
California Institute Of Technology |
Adeno-associated virus compositions for targeted gene therapy
|
|
EP3856762A1
(en)
|
2018-09-28 |
2021-08-04 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
EP3864160A4
(en)
*
|
2018-10-10 |
2022-10-26 |
Wisconsin Alumni Research Foundation |
KIR 7.1 GENE THERAPY VECTORS AND METHODS OF USING THE SAME
|
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
JP2022504740A
(ja)
*
|
2018-10-12 |
2022-01-13 |
ジェンザイム・コーポレーション |
肝臓に向けられた遺伝子補充療法によって重度のｐｋｕを処置するための改善されたヒトｐａｈの生成
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
US20230061069A1
(en)
*
|
2018-11-13 |
2023-03-02 |
Jayandharan Giridhara Rao |
A process for producing a plurality of sumoylation target-site modified aav vector and product thereof
|
|
JP2022513127A
(ja)
*
|
2018-11-26 |
2022-02-07 |
ウニベルシダッド アウトノマ デ バルセロナ |
線維芽細胞増殖因子２１（ｆｇｆ２１）遺伝子療法
|
|
CA3121247A1
(en)
|
2018-12-03 |
2020-06-11 |
Board Of Regents, The University Of Texas System |
Oligo-benzamide analogs and their use in cancer treatment
|
|
US20220089670A1
(en)
*
|
2018-12-28 |
2022-03-24 |
University Of Rochester |
Gene Therapy for BEST1 Dominant Mutations
|
|
SG11202106855YA
(en)
*
|
2019-01-04 |
2021-07-29 |
Ultragenyx Pharmaceutical Inc |
Gene therapy constructs for treating wilson disease
|
|
WO2020150556A1
(en)
|
2019-01-18 |
2020-07-23 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
|
CA3125294A1
(en)
*
|
2019-01-23 |
2020-07-30 |
University Of Florida Research Foundation, Incorporated |
Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design
|
|
JP2022518814A
(ja)
|
2019-01-28 |
2022-03-16 |
コーバー、インコーポレイテッド |
治療用ペプチド
|
|
JP7600124B2
(ja)
|
2019-02-04 |
2024-12-16 |
フリーライン セラピューティクス リミテッド |
ポリヌクレオチド
|
|
CN113710805A
(zh)
|
2019-03-04 |
2021-11-26 |
杜克大学 |
用于诊断和治疗视网膜病变的组合物和方法
|
|
EP3934698A1
(en)
*
|
2019-03-04 |
2022-01-12 |
Adverum Biotechnologies, Inc. |
Sequential intravitreal administration of aav gene therapy to contralateral eyes
|
|
US20220175961A1
(en)
*
|
2019-03-08 |
2022-06-09 |
Universite Paris-Saclay |
Improved therapeutic method for rare ocular diseases by gene replacement
|
|
BR112021018776A2
(pt)
|
2019-03-21 |
2021-11-30 |
Stridebio Inc |
Vetores de vírus adenoassociado recombinante
|
|
EP3953378A1
(en)
*
|
2019-04-10 |
2022-02-16 |
Prevail Therapeutics, Inc. |
Gene therapies for lysosomal disorders
|
|
US20240124889A1
(en)
|
2019-05-07 |
2024-04-18 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
CA3139852A1
(en)
*
|
2019-05-13 |
2020-11-19 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Polymer-based implant for retinal therapy and methods of making and using the same
|
|
KR20220009427A
(ko)
*
|
2019-05-17 |
2022-01-24 |
더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 |
글리코시드 가수분해효소를 사용하는 망막 세포에 대한 유전자 치료 벡터의 개선된 전달
|
|
KR20220035107A
(ko)
*
|
2019-06-10 |
2022-03-21 |
호몰로지 메디슨, 인크. |
Arsa 유전자 전달을 위한 아데노-연관 바이러스 조성물 및 이의 사용 방법
|
|
EP3989982A4
(en)
*
|
2019-06-27 |
2023-06-28 |
University Of Florida Research Foundation, Incorporated |
Enhancing aav-mediated transduction of ocular tissues with hyaluronic acid
|
|
US11446084B2
(en)
|
2019-07-12 |
2022-09-20 |
Neuralink Corp. |
Laser drilling of pia mater
|
|
CA3146791A1
(en)
*
|
2019-07-15 |
2021-01-21 |
Meiragtx Uk Ii Limited |
Modified aav capsid proteins for treatment of arthritic disease
|
|
CN110295151A
(zh)
*
|
2019-07-17 |
2019-10-01 |
博鑫仪器(天津)有限公司 |
一类腺依赖病毒病毒重组质粒、重组病毒及构建方法
|
|
WO2021041324A2
(en)
*
|
2019-08-23 |
2021-03-04 |
Duke University |
Compositions and methods for the treatment of pathological pain and itch
|
|
WO2021046169A1
(en)
*
|
2019-09-03 |
2021-03-11 |
University Of Cincinnati |
Methods and compositions for the treatment of als
|
|
US20220333133A1
(en)
|
2019-09-03 |
2022-10-20 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
AU2020363984A1
(en)
*
|
2019-10-10 |
2022-04-28 |
Solid Biosciences Inc. |
Modified aav capsids and uses thereof
|
|
CN114787180A
(zh)
|
2019-10-17 |
2022-07-22 |
斯特里迪比奥公司 |
用于治疗c型尼曼-匹克病的腺相关病毒载体
|
|
AU2020369570A1
(en)
*
|
2019-10-23 |
2022-05-12 |
The Trustees Of The University Of Pennsylvania |
Compositions for DRG-specific reduction of transgene expression
|
|
WO2021092300A1
(en)
*
|
2019-11-08 |
2021-05-14 |
President And Fellows Of Harvard College |
Viral capsid polypeptides
|
|
CN113025618B
(zh)
*
|
2019-12-24 |
2024-02-06 |
朗信启昇(苏州)生物制药有限公司 |
一种x连锁遗传性视网膜劈裂症的基因治疗方案与应用
|
|
MX2022009252A
(es)
*
|
2020-01-29 |
2022-11-09 |
Genzyme Corp |
Proteinas de la capside de virus adeno-asociados modificadas para la terapia genica ocular y metodos de uso de las mismas.
|
|
CA3167195A1
(en)
*
|
2020-02-07 |
2021-08-12 |
The Trustees Of Columbia University In The City Of New York |
Reprogramming the metabolome to delay onset or treat neurodegeneration
|
|
WO2021167919A1
(en)
*
|
2020-02-18 |
2021-08-26 |
The University Of North Carolina At Chapel Hill |
Aav capsid-promoter interactions and cell selective gene expression
|
|
EP4110913A4
(en)
*
|
2020-02-28 |
2024-07-24 |
University of Massachusetts |
OLIGONUCLEOTIDES FOR PRNP MODULATION
|
|
WO2021183779A1
(en)
|
2020-03-11 |
2021-09-16 |
Massachusetts Eye And Ear Infirmary |
Gene therapy for nmnat1-associated retinal degeneration
|
|
CN115698039A
(zh)
*
|
2020-03-31 |
2023-02-03 |
马萨诸塞大学 |
衣壳变体及其用途
|
|
JP2023523573A
(ja)
*
|
2020-04-14 |
2023-06-06 |
ジェネトン |
酸性セラミダーゼ欠乏症を処置するためのベクター
|
|
KR20230020394A
(ko)
|
2020-04-15 |
2023-02-10 |
보이저 테라퓨틱스, 인크. |
Tau 결합 화합물
|
|
PE20230767A1
(es)
|
2020-05-13 |
2023-05-09 |
Voyager Therapeutics Inc |
Redireccion del tropismo de las capsides de aav
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
EP4165193A4
(en)
*
|
2020-06-13 |
2024-07-24 |
Oculogenex Inc. |
AAV-MEDIATED GENE TRANSFER FOR RETINOPATHY
|
|
CN113952472A
(zh)
*
|
2020-07-21 |
2022-01-21 |
英斯培瑞有限公司 |
用于治疗眼部疾病的组合物和方法
|
|
WO2022017630A1
(en)
|
2020-07-23 |
2022-01-27 |
Ucl Business Ltd |
GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF
|
|
TW202221125A
(zh)
|
2020-07-27 |
2022-06-01 |
美商航海家醫療公司 |
用於治療與葡萄糖神經醯胺酶β缺陷相關之神經病症的組合物及方法
|
|
WO2022026410A2
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
JP2023536618A
(ja)
|
2020-08-05 |
2023-08-28 |
スペースクラフト セブン リミテッド ライアビリティ カンパニー |
Ｃｓｒｐ３（システイン及びグリシンリッチタンパク質３）遺伝子治療
|
|
IL300263A
(en)
|
2020-08-07 |
2023-03-01 |
Spacecraft Seven Llc |
Plakophilin-2 (PKP2) gene therapy using an AAV vector
|
|
US12104163B2
(en)
*
|
2020-08-19 |
2024-10-01 |
Sarepta Therapeutics, Inc. |
Adeno-associated virus vectors for treatment of Rett syndrome
|
|
US20230330267A1
(en)
*
|
2020-09-04 |
2023-10-19 |
Ohio State Innovation Foundation |
Novel engineered capsid serotype of recombinant adeno-associated viral vector with enhanced transduction efficiency and widespread distribution in the brain
|
|
US20230392166A1
(en)
*
|
2020-10-21 |
2023-12-07 |
Wisconsin Alumni Research Foundation |
Anti-apoptotic vector and method of using the same
|
|
US20220160825A1
(en)
*
|
2020-11-25 |
2022-05-26 |
The Penn State Research Foundation |
Brain repair after traumatic brain injury through neurod1-mediated astrocyte-to-neuron conversion
|
|
CN117157091A
(zh)
*
|
2021-02-22 |
2023-12-01 |
科罗拉多大学董事会法人团体 |
基于病毒载体的眼部病症的基因治疗
|
|
CN115044614B
(zh)
*
|
2021-03-09 |
2023-10-20 |
上海目镜生物医药科技有限公司 |
一种用于基因靶向与表达的aav-8型血清型的改造型载体及其构建方法及应用
|
|
WO2022231950A1
(en)
*
|
2021-04-26 |
2022-11-03 |
Grace Science, Llc |
Compositions and methods for treating ngyl1 deficiency
|
|
CA3231028A1
(en)
*
|
2021-09-06 |
2023-03-09 |
Shaoran Wang |
Treatment of rpe65-associated eye diseases and disorders
|
|
US20250049955A1
(en)
|
2021-11-17 |
2025-02-13 |
Voyager Therapeutics, Inc. |
Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
WO2023093905A1
(zh)
|
2021-11-29 |
2023-06-01 |
上海瑞宏迪医药有限公司 |
Aadc、gdnf多核苷酸及其用于治疗帕金森病
|
|
WO2023155918A1
(zh)
|
2022-02-21 |
2023-08-24 |
上海瑞宏迪医药有限公司 |
Vegf结合分子及其医药用途
|
|
EP4499154A1
(en)
*
|
2022-03-25 |
2025-02-05 |
REGENXBIO Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
|
WO2023202637A1
(en)
*
|
2022-04-19 |
2023-10-26 |
Shanghai Vitalgen Biopharma Co., Ltd. |
Recombinant aav vectors for treating neurodegenerative disorders
|
|
AU2023260469A1
(en)
|
2022-04-25 |
2024-11-14 |
Cell Cure Neurosciences, Ltd. |
Methods and compositions for treating vision loss
|
|
EP4514402A2
(en)
*
|
2022-04-25 |
2025-03-05 |
Myrtelle Inc. |
Treatments of disorders of myelin
|
|
IL316327A
(en)
|
2022-05-06 |
2024-12-01 |
Novartis Ag |
AAV VP2 fusion polypeptide novel recombinant
|
|
WO2023240220A1
(en)
*
|
2022-06-09 |
2023-12-14 |
The University Of North Carolina At Chapel Hill |
Aav-sgsh vectors for treatment of mucopolysaccharidosis iiia
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
EP4303226A1
(en)
|
2022-07-08 |
2024-01-10 |
Ospedale San Raffaele S.r.l. |
Transgene cassettes and epigenetic silencers for the treatment of disorders
|
|
EP4551253A1
(en)
|
2022-07-08 |
2025-05-14 |
Ospedale San Raffaele S.r.l. |
Transgene cassettes
|
|
EP4555097A2
(en)
*
|
2022-07-12 |
2025-05-21 |
The Research Institute at Nationwide Children's Hospital |
Adeno-associated virus gene therapy products and methods
|
|
WO2024163012A1
(en)
|
2023-02-02 |
2024-08-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
WO2024218311A1
(fr)
|
2023-04-21 |
2024-10-24 |
Pulsesight Therapeutics |
Compositions à base de décorine pour la réparation et la régéneration de l'épithélium pigmentaire de la rétine
|
|
GB202306952D0
(en)
*
|
2023-05-11 |
2023-06-28 |
Neurochase Innovations Ltd |
Method
|
|
US20250197862A1
(en)
|
2023-12-15 |
2025-06-19 |
Genzyme Corporation |
ARTIFICIAL microRNAs TARGETING TAU
|
|
WO2025160452A1
(en)
|
2024-01-25 |
2025-07-31 |
Genzyme Corporation |
Methods for fus-based delivery of viral particles to the brain
|
|
WO2025160429A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting snca
|
|
WO2025160434A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting huntington's disease
|